Monopar Therapeutics Inc. ( MNPR) Stock. Should you Buy or Sell? $ 1.74
0.03 (1.69 %)
Monopar Therapeutics Inc. Analysis
Updated on 10-09-2022| Symbol | MNPR |
| Price | $1.74 |
| Beta | 0.472 |
| Volume Avg. | $10.44 thousand |
| Market Cap | $22.14 M |
| 52 Week Range | $1.63 - $5.82 |
Monopar Therapeutics Inc. opened the day at $1.74 which is +'1.69 % on yesterday's close. Monopar Therapeutics Inc. has a 52 week high of $5.82 and 52 week low of $1.63, which is a difference of $4.19. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $22.14 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Monopar Therapeutics Inc. for $22.14 M, it would take 15 years to get your money back. Monopar Therapeutics Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Monopar Therapeutics Inc. Stock Forecast - Is Monopar Therapeutics Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | 0.000 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Monopar Therapeutics Inc.
| Price Book Value Ratio | 1.514 | Price To Book Ratio | 1.514 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | 0.000 |
How liquid is Monopar Therapeutics Inc.
| Current Ratio | 7.614 |
| Quick Ratio | 7.528 |
Debt
| Debt Ratio | 0.133 | Debt Equity Ratio | 0.153 |
| Long Term Debt To Capitalization | 0.002 | Total Debt To Capitalization | 0.000 |
Latest news about Monopar Therapeutics Inc.
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will present at the 34th Annual Roth Conference and Maxim's 2022 Virtual Growth Conference.
WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00am ET. Presentation Details:
WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced its Phase 1b open-label dose-escalation clinical trial of camsirubicin in the US is active and recruiting patients. The trial is evaluating the safety and anti-tumor activity of increasing doses of camsirubicin in combination with growth factor support (pegfilgrastim/G-CSF) for the treatment of advanced soft tissue sarcoma (ASTS).
WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has successfully reached its target of 20 activated clinical trial sites in the Phase 2b portion of the VOICE trial.
About Monopar Therapeutics Inc.
Description :
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
